H 001
Alternative Names: H-001; RIPTAC therapeutics; RIPTAC™Latest Information Update: 08 Oct 2024
At a glance
- Originator Halda Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 01 Oct 2024 Halda Therapeutics plans a phase I trial for Prostrate cancer (Metastatic disease, Hormone-refractory) in 2025
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Prostate cancer presented at the American Association for Cancer Research (AACR-2023)
- 21 Feb 2023 Pharmacodynamics data from a preclinical trial in Prostate cancer released by Halda Therapeutics